Table 1 Clinical Data of Patients on CAR T-Cell Therapy
CAR19/22 (N = 84) | CAR-BCMA (N = 16) | HSCT + CAR-19/22 (N = 9) | Total (N = 109) | |
|---|---|---|---|---|
Age | ||||
Years, median (range) | 47 (15–67) | 55 (34–69) | 40 (25–61) | 47 (15–67) |
Sex | ||||
Female | 38 (45.2) | 3 (18.8) | 1 (11.1) | 42 (38.5) |
Diseases | ||||
B-ALL | 25 (29.8) | – | – | 25 (22.9) |
B-cell lymphoma | 59 (70.2) | – | 9 (100.0) | 68 (62.4) |
MM | – | 16 (100.0) | – | 16 (14.7) |
Refractory or relapse | ||||
Primary refractory | 21 (25.0) | 3 (18.8) | 4 (44.4) | 28 (25.7) |
First relapse | 30 (35.7) | 3 (18.8) | 1 (11.1) | 34 (31.2) |
≥ Second relapse | 33 (39.3) | 10 (62.5) | 4 (44.4) | 47 (43.1) |
Prior HSCT | ||||
Autologous | 15 (17.9) | 7 (43.8) | 0 (0.0) | 22 (20.2) |
Allogeneic | 3 (3.6) | 0 (0.0) | 0 (0.0) | 3 (2.8) |
CAR-T cell dose, ×106 cells/kg, median (range) | ||||
CART19 | 4.0 (1–10.0) | – | 3.3 (1.8–10.0) | 4.0 (1.0–10.0) |
CART22 | 4.8 (1–13.5) | – | 4.2 (1.8–10.0) | 4.6 (1.0–13.5) |
CART-BCMA | – | 9.9 (5.4–20.0) | – | 9.9 (5.4–20.0) |
Neutropenia duration | ||||
Days, median (range) | 12 (0–30) | 7 (2–16) | 11 (2–15) | 11 (0–30) |
CRS grading | ||||
Grade 0–2 | 75 (89.3) | 14 (87.5) | 9 (100.0) | 98 (89.9) |
Grade 3–5 | 9 (10.7) | 2 (12.5) | 0 (0.0) | 11 (10.1) |
Overall response ratea | 70 (83.3) | 13 (81.3) | 8 (88.9) | 91 (83.5) |